Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF Polymorphisms and Bevacizumab Efficacy in Metastatic Colorectal Cancer
NCT06843954Phase 4Completed
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in metastatic colorectal cancer (mCRC). Primary endpoints: Complete Response Rate, Partial Response Rate and 6 more. Started Sep 2022; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06843954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843954.